Inari Medical’s (NARI) Market Perform Rating Reaffirmed at William Blair

William Blair restated their market perform rating on shares of Inari Medical (NASDAQ:NARI) in a research report report published on Tuesday, Marketbeat reports.

Other equities analysts have also recently issued research reports about the company. Truist Financial lifted their price objective on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective (down from $81.00) on shares of Inari Medical in a research report on Tuesday. Piper Sandler lifted their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday. Oppenheimer began coverage on Inari Medical in a report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a report on Tuesday. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $68.00.

Inari Medical Trading Up 22.2 %

Inari Medical stock opened at $79.45 on Tuesday. The firm has a market capitalization of $4.65 billion, a P/E ratio of -58.85 and a beta of 0.97. The stock’s fifty day simple moving average is $52.85 and its 200-day simple moving average is $48.92. Inari Medical has a twelve month low of $36.73 and a twelve month high of $79.50.

Insider Activity

In related news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now directly owns 601,233 shares of the company’s stock, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 206,000 shares of company stock worth $10,527,870 in the last 90 days. 10.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Inari Medical

A number of hedge funds and other institutional investors have recently modified their holdings of NARI. Arizona State Retirement System lifted its stake in shares of Inari Medical by 2.5% during the second quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock valued at $703,000 after buying an additional 358 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after purchasing an additional 473 shares during the last quarter. KBC Group NV lifted its position in Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares during the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Inari Medical by 2.8% during the 3rd quarter. Cerity Partners LLC now owns 24,056 shares of the company’s stock worth $992,000 after acquiring an additional 652 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.